Programmed Necrosis Inducers for Cancer Treatment.
10.3881/j.issn.1000-503X.13241
- Author:
Qi ZHAO
1
;
Li-Jun YANG
1
;
Yan-Bo ZHENG
2
;
Jian-Hua GONG
2
Author Information
1. Department of Pharmacology,Shanxi Medical University,Taiyuan 030001,China.
2. Department of Oncology,Institute of Medicinal Biotechnology,CAMS and PUMC,Beijing 100050,China.
- Publication Type:Journal Article
- Keywords:
apoptosis resistance;
mixed lineage kinase domain-like protein;
programmed necrosis inducer;
tumor
- MeSH:
Apoptosis;
Cell Death;
Humans;
Necrosis/pathology*;
Neoplasms/drug therapy*;
Protein Kinases/pharmacology*
- From:
Acta Academiae Medicinae Sinicae
2022;44(2):338-347
- CountryChina
- Language:Chinese
-
Abstract:
Programmed necrosis,a mode of cell death independent of Caspase,is mainly mediated by receptor-interacting protein kinase-1 (RIPK1),receptor-interacting protein kinase-3 (RIPK3),and mixed lineage kinase domain-like protein (MLKL).Studies have demonstrated that programmed necrosis has the dual role of promoting and inhibiting tumor growth and thus we can control the development of tumor by regulating programmed necrosis.The drugs capable of inducing programmed necrosis show potential anti-tumor activity.In addition,inducing programmed necrosis is an effective way to overcome tumor resistance to apoptosis.This paper summarized the mechanisms of programmed necrosis and its relationship with tumors.We focused on the antitumor activity of programmed necrosis inducers including natural products,chemotherapeutic drugs,death receptor ligands,kinase inhibitors,inorganic salts,metal complexes,and metal nanoparticles.These agents will provide new therapeutic candidates for the treatment of tumors,especially the tumors acquiring resistance to apoptosis.
